Sonoma Pharmaceuticals, Inc. (SNOA)
USD 1.88
(-1.57%)
USD 1.88
(-1.57%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 14.89 Million USD | -9.19% |
| 2023 | 16.23 Million USD | -13.87% |
| 2022 | 18.84 Million USD | 25.74% |
| 2021 | 14.98 Million USD | 2.93% |
| 2020 | 14.56 Million USD | 0.78% |
| 2019 | 14.44 Million USD | -24.77% |
| 2018 | 19.2 Million USD | -24.56% |
| 2017 | 25.45 Million USD | 84.45% |
| 2016 | 13.8 Million USD | -8.27% |
| 2015 | 15.04 Million USD | -27.62% |
| 2014 | 20.79 Million USD | 65.47% |
| 2013 | 12.56 Million USD | 60.31% |
| 2012 | 7.83 Million USD | -9.53% |
| 2011 | 8.66 Million USD | -15.21% |
| 2010 | 10.21 Million USD | 87.59% |
| 2009 | 5.44 Million USD | -76.93% |
| 2008 | 23.61 Million USD | -12.39% |
| 2007 | 26.95 Million USD | 112.39% |
| 2006 | 12.68 Million USD | 82.84% |
| 2005 | 6.94 Million USD | 0.0% |
| 2003 | 961 Thousand USD | -43.03% |
| 2002 | 1.68 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 13.63 Million USD | -14.21% |
| 2024 Q3 | 14.61 Million USD | 7.21% |
| 2024 Q4 | 14.89 Million USD | 1.88% |
| 2024 FY | 14.89 Million USD | -8.24% |
| 2024 Q1 | 15.89 Million USD | -2.08% |
| 2023 FY | 16.23 Million USD | -13.87% |
| 2023 Q3 | 13.92 Million USD | -6.91% |
| 2023 Q2 | 14.96 Million USD | -12.8% |
| 2023 Q4 | 16.23 Million USD | 16.54% |
| 2023 Q1 | 17.15 Million USD | -8.95% |
| 2022 FY | 18.84 Million USD | 25.74% |
| 2022 Q4 | 18.84 Million USD | -2.59% |
| 2022 Q3 | 19.34 Million USD | -2.43% |
| 2022 Q2 | 19.82 Million USD | 40.41% |
| 2022 Q1 | 14.12 Million USD | -5.78% |
| 2021 Q3 | 18.23 Million USD | 0.47% |
| 2021 Q2 | 18.14 Million USD | -2.72% |
| 2021 FY | 14.98 Million USD | 2.93% |
| 2021 Q1 | 18.65 Million USD | 28.1% |
| 2021 Q4 | 14.98 Million USD | -17.79% |
| 2020 Q3 | 16.49 Million USD | 2.17% |
| 2020 FY | 14.56 Million USD | 0.78% |
| 2020 Q1 | 16.91 Million USD | 17.1% |
| 2020 Q4 | 14.56 Million USD | -11.73% |
| 2020 Q2 | 16.14 Million USD | -4.57% |
| 2019 Q3 | 17.04 Million USD | 18.8% |
| 2019 FY | 14.44 Million USD | -24.77% |
| 2019 Q1 | 16.63 Million USD | -13.4% |
| 2019 Q2 | 14.34 Million USD | -13.74% |
| 2019 Q4 | 14.44 Million USD | -15.24% |
| 2018 Q2 | 20.15 Million USD | -10.12% |
| 2018 FY | 19.2 Million USD | -24.56% |
| 2018 Q4 | 19.2 Million USD | 4.64% |
| 2018 Q3 | 18.35 Million USD | -8.92% |
| 2018 Q1 | 22.42 Million USD | -11.93% |
| 2017 FY | 25.45 Million USD | 84.45% |
| 2017 Q4 | 25.45 Million USD | -7.45% |
| 2017 Q3 | 27.5 Million USD | 197.66% |
| 2017 Q2 | 9.24 Million USD | -18.37% |
| 2017 Q1 | 11.32 Million USD | -17.99% |
| 2016 FY | 13.8 Million USD | -8.27% |
| 2016 Q2 | 13.58 Million USD | -4.38% |
| 2016 Q1 | 14.2 Million USD | -5.6% |
| 2016 Q3 | 12.09 Million USD | -10.94% |
| 2016 Q4 | 13.8 Million USD | 14.09% |
| 2015 Q3 | 11.83 Million USD | -35.66% |
| 2015 Q2 | 18.39 Million USD | -7.47% |
| 2015 Q1 | 19.87 Million USD | -4.39% |
| 2015 Q4 | 15.04 Million USD | 27.16% |
| 2015 FY | 15.04 Million USD | -27.62% |
| 2014 Q2 | 8.88 Million USD | -16.06% |
| 2014 Q4 | 20.79 Million USD | 111.23% |
| 2014 Q1 | 10.58 Million USD | -15.79% |
| 2014 Q3 | 9.84 Million USD | 10.82% |
| 2014 FY | 20.79 Million USD | 65.47% |
| 2013 Q1 | 9.69 Million USD | 23.67% |
| 2013 Q4 | 12.56 Million USD | 6.21% |
| 2013 Q3 | 11.83 Million USD | -11.66% |
| 2013 Q2 | 13.39 Million USD | 38.16% |
| 2013 FY | 12.56 Million USD | 60.31% |
| 2012 Q1 | 9.21 Million USD | 6.3% |
| 2012 FY | 7.83 Million USD | -9.53% |
| 2012 Q4 | 7.83 Million USD | -12.73% |
| 2012 Q3 | 8.98 Million USD | 15.69% |
| 2012 Q2 | 7.76 Million USD | -15.71% |
| 2011 FY | 8.66 Million USD | -15.21% |
| 2011 Q4 | 8.66 Million USD | 2.98% |
| 2011 Q3 | 8.41 Million USD | -9.57% |
| 2011 Q1 | 10.37 Million USD | 1.53% |
| 2011 Q2 | 9.3 Million USD | -10.32% |
| 2010 Q2 | 9.97 Million USD | 69.67% |
| 2010 Q4 | 10.21 Million USD | 19.15% |
| 2010 Q3 | 8.57 Million USD | -13.98% |
| 2010 FY | 10.21 Million USD | 87.59% |
| 2010 Q1 | 5.87 Million USD | 7.88% |
| 2009 Q2 | 9.77 Million USD | -39.52% |
| 2009 Q4 | 5.44 Million USD | -6.68% |
| 2009 FY | 5.44 Million USD | -76.93% |
| 2009 Q1 | 16.16 Million USD | -31.54% |
| 2009 Q3 | 5.83 Million USD | -40.3% |
| 2008 Q1 | 20.53 Million USD | -23.8% |
| 2008 Q2 | 20.04 Million USD | -2.42% |
| 2008 Q3 | 14.89 Million USD | -25.68% |
| 2008 Q4 | 23.61 Million USD | 58.54% |
| 2008 FY | 23.61 Million USD | -12.39% |
| 2007 FY | 26.95 Million USD | 112.39% |
| 2007 Q3 | 9.8 Million USD | -2.55% |
| 2007 Q2 | 10.05 Million USD | 0.0% |
| 2007 Q4 | 26.95 Million USD | 175.0% |
| 2006 Q4 | 12.68 Million USD | 0.0% |
| 2006 FY | 12.68 Million USD | 82.84% |
| 2005 Q4 | 6.94 Million USD | 0.0% |
| 2005 FY | 6.94 Million USD | 0.0% |
| 2003 FY | 961 Thousand USD | -43.03% |
| 2002 FY | 1.68 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Journey Medical Corporation | 76.84 Million USD | 80.62% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 98.353% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | 74.062% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 99.054% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | 45.541% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | 45.541% |
| SCYNEXIS, Inc. | 128.41 Million USD | 88.402% |
| Safety Shot Inc | 12.7 Million USD | -17.183% |
| Alpha Teknova, Inc. | 128.58 Million USD | 88.418% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 98.697% |
| Bright Green Corporation | 17.4 Million USD | 14.423% |
| Dynavax Technologies Corporation | 997.09 Million USD | 98.506% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 92.763% |
| Cosmos Health Inc. | 66.29 Million USD | 77.535% |
| PainReform Ltd. | 9.93 Million USD | -49.98% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | 35.604% |
| Embecta Corp. | 1.21 Billion USD | 98.774% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 97.955% |
| Procaps Group, S.A. | 460.18 Million USD | 96.764% |
| Theratechnologies Inc. | 77.76 Million USD | 80.85% |
| Harrow Health, Inc. | 311.75 Million USD | 95.223% |
| Biofrontera Inc. | 27.93 Million USD | 46.681% |
| DURECT Corporation | 45.18 Million USD | 67.043% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 98.943% |
| Cronos Group Inc. | 1.13 Billion USD | 98.687% |
| OptiNose, Inc. | 107.72 Million USD | 86.175% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 96.838% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 73.381% |
| RedHill Biopharma Ltd. | 23.04 Million USD | 35.38% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 96.763% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -24.96% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 81.788% |
| Radius Health, Inc. | 1.71 Billion USD | 99.132% |
| Universe Pharmaceuticals INC | 53.28 Million USD | 72.051% |
| ProPhase Labs, Inc. | 91.92 Million USD | 83.799% |
| Phibro Animal Health Corporation | 982.18 Million USD | 98.484% |
| Procaps Group S.A. | 460.18 Million USD | 96.764% |
| Alvotech | 950.09 Million USD | 98.432% |
| TherapeuticsMD, Inc. | 43.3 Million USD | 65.612% |
| Viatris Inc. | 47.68 Billion USD | 99.969% |
| Rockwell Medical, Inc. | 52.17 Million USD | 71.455% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 87.389% |
| SIGA Technologies, Inc. | 254.83 Million USD | 94.156% |
| Tilray Brands, Inc. | 4.33 Billion USD | 99.656% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 94.559% |
| Shineco, Inc. | 84.17 Million USD | 82.308% |
| PetIQ, Inc. | 868.22 Million USD | 98.285% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -76.495% |
| Incannex Healthcare Limited | 17.04 Million USD | 12.636% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 99.542% |
| Alimera Sciences, Inc. | 153.52 Million USD | 90.299% |
| Silver Spike Investment Corp. | 88.57 Million USD | 83.186% |
| Assertio Holdings, Inc. | 286.41 Million USD | 94.8% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -150.23% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | 55.932% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | 52.332% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -12.421% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 94.297% |
| Hempacco Co., Inc. | 18.04 Million USD | 17.459% |
| Talphera, Inc. | 20.39 Million USD | 26.977% |
| Alvotech | 950.09 Million USD | 98.432% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 96.333% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 99.098% |
| Currenc Group, Inc. | 141.49 Million USD | 89.474% |
| Kamada Ltd. | 351.96 Million USD | 95.769% |
| Indivior PLC | 1.95 Billion USD | 99.237% |
| Evoke Pharma, Inc. | 7.06 Million USD | -110.694% |
| Flora Growth Corp. | 23.62 Million USD | 36.964% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -12.421% |
| Evolus, Inc. | 188.99 Million USD | 92.12% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 98.836% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 99.016% |
| Akanda Corp. | 8.83 Million USD | -68.473% |